Birch Allergy Market

Key Highlights

• Birch (followed by alder and hazel) is the most problematic tree allergen. There are seven types of birch pollen allergens, but the main one is called Bet v 1 specific IgE. High levels of IgE to Bet v 1 are more commonly associated with oral allergy syndrome.
• Birch pollen allergy gets triggered by birch tree pollen. Birch pollen is a prominent elicitor of allergies affecting approximately 8-16% of individuals.
• The market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness.
• The United States accounts for the largest market size of Birch pollen allergy, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• ITULAZAX are pivotal drugs for birch pollen allergy and hold approval exclusively within the European market.
• The key target in the Birch pollen allergy pipeline drugs is Pollen Allergen Bet v 1.
• Birch pollen allergy pipeline is not so robust but possesses potential drugs i.e. REGN5713-5714-5715 (Bet v1 monoclonal antibodies).

DelveInsight's “Birch pollen allergy – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Birch pollen allergy, historical and forecasted epidemiology as well as the Birch pollen allergy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Birch pollen allergy market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Birch pollen allergy market size from 2020 to 2034. The report also covers current Birch pollen allergy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Birch pollen allergy Understanding and Treatment Algorithm

Birch pollen allergy Overview, Country-Specific Treatment Guidelines and Diagnosis

Birch pollen allergy is a common allergic condition caused by the pollen of birch trees. It is characterized by symptoms such as sneezing, runny nose, itchy eyes, and congestion, which typically occur during the birch pollen season. The allergy is caused by the body's overreaction to the Bet v 1 protein in birch pollen, which triggers the release of histamine and other chemical mediators, leading to the symptoms of allergic rhinitis.

Diagnosis of birch pollen allergy typically involves a combination of medical history, physical examination, and allergy testing. The medical history includes questions about symptoms, exposure to birch pollen, and family history of allergies. Physical examination may include inspection of the eyes, nose, and throat for signs of allergic reactions. Allergy testing involves skin prick testing or blood tests to measure the levels of IgE antibodies against birch pollen.

Further details related to country-based variations in diagnosis are provided in the report.

Birch pollen allergy Treatment

Treatment of birch pollen allergy typically involves a combination of avoidance measures, medications, and immunotherapy. Avoidance measures include staying indoors during peak pollen hours, keeping windows closed, and using air conditioning. Medications such as antihistamines, decongestants, and corticosteroids can help alleviate symptoms. Immunotherapy, such as sublingual immunotherapy (SLIT), involves the gradual introduction of birch pollen extracts to the body to desensitize the patient to the allergen.

Birch pollen allergy Epidemiology

The Birch pollen allergy epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Birch pollen allergy epidemiology is segmented with detailed insights into prevalence cases, age-specific cases, gender-specific cases, and allergy-specific cases of Birch pollen allergy.

• • Birch pollen allergy exhibits a higher prevalence among females, with approximately 70% of cases occurring in females.
• • Among European patients with pollen allergies, there is a notably high prevalence of Bet v 1 sensitization, reaching approximately 55%.
• • Approximately 70% of birch pollen–allergic patients experience hypersensitivity reactions to IgE cross-reacting food sources.

Birch pollen allergy Drug Chapter 

The drug chapter segment of the Birch pollen allergy report encloses a detailed analysis of Birch pollen allergy marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Birch pollen allergy pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Marketed Drugs

ITULAZAX: ALK-Abello

ITULAZAX is a sublingual immunotherapy tablet developed by ALK-Abello A/S for the treatment of adults with moderate-to-severe allergic rhinitis (AR) and/or conjunctivitis induced by pollen from the birch tree. It is designed to provide long-term relief from birch pollen allergy symptoms. The tablet is administered sublingually and is effective in reducing symptoms and improving the quality of life for patients with birch pollen allergy.

The mechanism involves the administration of the allergen extract under the tongue, which triggers an immune response that helps to desensitize the patient to birch pollen over time. It was approved in the EU in 2019.

Note: Detailed current therapies assessment will be provided in the full report of Birch pollen allergy

Emerging Drugs

REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies developed by Regeneron Pharmaceuticals for the treatment of birch pollen allergy. The mechanism of action involves the inhibition of Bet v 1, a major birch pollen allergen, by binding to IgE receptors and preventing the activation of mast cells and basophils, thereby reducing the allergic response.

Regeneron is currently conducting a Phase III study to further evaluate the efficacy and safety of REGN5713-5714-5715 in a larger population of patients with birch pollen allergy.

Note: Detailed emerging therapies assessment will be provided in the final report.

Birch pollen allergy Market Outlook

Key players, such as Regeneron Pharmaceuticals, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Birch pollen allergy.

• • Regeneron Pharmaceuticals, a key player in the market, is spearheading the development of groundbreaking treatments for birch pollen allergy, establishing its dominance in the field.
• • The challenge in birch pollen allergy treatment lies in addressing the inadequate options for moderate to severe allergic rhinitis and conjunctivitis. 
• • Existing treatments like antihistamines and corticosteroids are frequently ineffective and can carry notable side effects. 

Birch pollen allergy Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Birch pollen allergy Activities

The report provides insights into therapeutic candidates in the Phase III stage. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Birch pollen allergy emerging therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Birch pollen allergy. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Birch pollen allergy, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Birch pollen allergy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Birch pollen allergy market.

Birch pollen allergy Report Insights

• Patient Population
• Therapeutic Approaches
• Birch pollen allergy Pipeline Analysis
• Birch pollen allergy Market Size and Trends
• Existing and future Market Opportunity 

Birch pollen allergy Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage 
• Birch pollen allergy Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Birch pollen allergy Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the growth rate of the 7MM Birch pollen allergy treatment market?
• What was the Birch pollen allergy total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Birch pollen allergy? 
• How many companies are developing therapies for the treatment of Birch pollen allergy?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Birch pollen allergy Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.